Endocrine-Related Cancer

Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by @soc_endo.

[Endocrine-Related Cancer @EndoCancer]

📢 Endocrine-Related Cancer is pausing activity on X.

To stay up to date with journal news and research, follow us on:

🌐LinkedIn: https://t.co/k66BVrE8s0
🦋Bluesky: https://t.co/j5kNB5fL5F

Thanks for staying connected and being part of our community!

[Endocrine-Related Cancer @EndoCancer]

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.

The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.

Register now: https://t.co/CUKFDhT5mV

#NETresearch

[Neuroendocrine Cancer Research Foundation @CureNETs]

Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: https://t.co/1lnW5BH3AW

[Endocrine-Related Cancer @EndoCancer]

🔬 Discovery of a novel sodium iodide symporter (NIS) regulatory pathway in breast cancer cells.

@Vikki_L_Poole et al. opens new therapeutic avenues in #BreastCancer by mapping NIS regulation & pinpointing targets to boost RAI-avidity.

Read #OpenAccess: https://t.co/R7Yro9ovSz

[Endocrine-Related Cancer @EndoCancer]

New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?

Subscribers can read the research: https://t.co/JWHI4pfMsc

[Endocrine-Related Cancer @EndoCancer]

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!

We welcome basic, translational & clinical studies that advance understanding & showcase innovations.

📩Submit your proposal to: [email protected]
🌐More info: https://t.co/0zbvtYYt2H

[Endocrine-Related Cancer @EndoCancer]

🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.

A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.

🔗https://t.co/l2tmL3FcbC

[Endocrine-Related Cancer @EndoCancer]

🌱Endocrine-Related Cancer is officially on LinkedIn!

Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal:

🌐https://t.co/k66BVrDACs

[Endocrine-Related Cancer @EndoCancer]

✨Systems biology approaches are reshaping our understanding of cancer.

Latest review by Michael V Orman et al. (@CUPharmacology) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.

#OpenAccess - https://t.co/PB2EqiYhwr

[Endocrine-Related Cancer @EndoCancer]

🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at @Griffith_Health, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.

Explore his recent research article on the rising incidence of thyroid cancer: https://t.co/B6xzgDcEs6

[Endocrine-Related Cancer @EndoCancer]

Sponsored by @CureNETs, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.

Learn more: https://t.co/eQ1lrOsSe6

#neuroendocrinecancer #earlycareerresearcher

[Endocrine-Related Cancer @EndoCancer]

🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?

Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.

🔗Explore the results: https://t.co/X0arE7WWQa

[Endocrine-Related Cancer @EndoCancer]

How do treatments for neuroendocrine neoplasms impact quality of life?

A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on QoL in NEN survivors.

📖 Read more: https://t.co/gRg58TKYYp

[Endocrine-Related Cancer @EndoCancer]

✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!

Dr. Pacak's term begins on 1st January 2026.

We are excited for this next chapter, driven by his expertise and vision🚀

[Endocrine-Related Cancer @EndoCancer]

🧪New research by Jinheng Xiao et al. explores the distinct metabolic profiles of parathyroid carcinoma and parathyroid adenoma, identifying promising biomarkers for preoperative diagnosis of parathyroid carcinoma.

Read the full article #OpenAccess: https://t.co/0SMVs38q3A

[Endocrine-Related Cancer @EndoCancer]

📢Are you attending #ENDO2025? Come and visit the Bioscientifica booth, 803, to find out more about publishing in Endocrine-Related Cancer!🙌✨

[Endocrine-Related Cancer @EndoCancer]

🧬New research by Mina Sattari (@Tays_sairaala) et al. identifies 85 metastatic castration-resistant prostate cancer-associated genes, spotlighting TMEM18 as a promising prognostic biomarker in early prostate cancer.

Explore the full article #OpenAccess: https://t.co/kf43Y31w5M

[Endocrine-Related Cancer @EndoCancer]

🆕Endocrine-Related Cancer is now on Bluesky.

Join us to stay up-to-date with research updates and news from Endocrine-Related Cancer, including the latest articles and developments in endocrine oncology.

🦋https://t.co/CMfACuFWDp🦋

[Endocrine-Related Cancer @EndoCancer]

We’re proud to share a message from our Editor-in-Chief following the news of our increased Journal Impact Factor, placing Endocrine-Related Cancer in Q1 for both 'Endocrinology & Metabolism' and 'Oncology' categories!
👇

[Endocrine-Related Cancer @EndoCancer]

Delighted to have achieved an increased Journal Impact Factor of 4.6 in the latest #JCR2025 report @ClarivateAG!

Thanks to our authors, reviewers and editors for your valued contributions & collaboration.

Explore the top-cited articles that contributed👉 https://t.co/qfPLla8Amn